NASDAQ:ABVC ABVC BioPharma (ABVC) Stock Price, News & Analysis $1.03 -0.03 (-2.83%) Closing price 04:00 PM EasternExtended Trading$1.03 0.00 (-0.19%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ABVC BioPharma Stock (NASDAQ:ABVC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ABVC BioPharma alerts:Sign Up Key Stats Today's Range$1.01▼$1.0650-Day Range$0.63▼$1.3252-Week Range$0.40▼$1.40Volume124,722 shsAverage Volume299,399 shsMarket Capitalization$16.25 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.Read More… ABVC BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreABVC MarketRank™: ABVC BioPharma scored higher than 15% of companies evaluated by MarketBeat, and ranked 874th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for ABVC BioPharma. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of ABVC BioPharma is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ABVC BioPharma is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioABVC BioPharma has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.87% of the float of ABVC BioPharma has been sold short.Short Interest Ratio / Days to CoverABVC BioPharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABVC BioPharma has recently decreased by 11.41%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldABVC BioPharma does not currently pay a dividend.Dividend GrowthABVC BioPharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.87% of the float of ABVC BioPharma has been sold short.Short Interest Ratio / Days to CoverABVC BioPharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABVC BioPharma has recently decreased by 11.41%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.46 News SentimentABVC BioPharma has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ABVC BioPharma this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ABVC BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders11.90% of the stock of ABVC BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.38% of the stock of ABVC BioPharma is held by institutions.Read more about ABVC BioPharma's insider trading history. Receive ABVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ABVC Stock News HeadlinesABVC BioPharma Announces First Quarter 2025 Financial Results and Strategic Planning for AI-Driven Agricultural Project in TaiwanMay 1 at 1:33 PM | finance.yahoo.comUPDATE: ABVC BioPharma Announces 2024 Financial ResultsApril 18, 2025 | nasdaq.comThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.May 1, 2025 | Stansberry Research (Ad)EQS-News: UPDATE: ABVC BioPharma Announces 2024 Financial ResultsApril 16, 2025 | markets.businessinsider.comABVC BioPharma Announces 2024 Financial ResultsApril 15, 2025 | finance.yahoo.comEQS-News: ABVC BioPharma Announces 2024 Financial ResultsApril 15, 2025 | markets.businessinsider.comEQS-News: ABVC's Subsidiary AiBtl Signs Share-for-Land Agreement in Asia With Deal Valued at USD $7.67 MillionApril 3, 2025 | markets.businessinsider.comABVC's Subsidiary AiBtl Signs Share-for-Land Agreement in Asia With Deal Valued at USD $7.67 MillionApril 3, 2025 | finance.yahoo.comSee More Headlines ABVC Stock Analysis - Frequently Asked Questions How have ABVC shares performed this year? ABVC BioPharma's stock was trading at $0.59 on January 1st, 2025. Since then, ABVC shares have increased by 74.6% and is now trading at $1.03. View the best growth stocks for 2025 here. How were ABVC BioPharma's earnings last quarter? ABVC BioPharma, Inc. (NASDAQ:ABVC) announced its quarterly earnings results on Wednesday, April, 30th. The company reported ($0.06) EPS for the quarter. ABVC BioPharma had a negative net margin of 1,619.65% and a negative trailing twelve-month return on equity of 104.94%. When did ABVC BioPharma's stock split? ABVC BioPharma shares reverse split before market open on Tuesday, July 25th 2023. The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did ABVC BioPharma IPO? ABVC BioPharma (ABVC) raised $7 million in an initial public offering (IPO) on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at a price of $6.25 per share. How do I buy shares of ABVC BioPharma? Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ABVC BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ABVC BioPharma investors own include Meta Platforms (META), NIO (NIO), ObsEva (OBSV), Tesla (TSLA), Alibaba Group (BABA), ChargePoint (CHPT) and Walt Disney (DIS). Company Calendar Last Earnings4/30/2025Today5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABVC CIK1173313 Webwww.abvcpharma.com Phone(510)-668-0881FaxN/AEmployees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,520,000.00 Net Margins-1,619.65% Pretax Margin-1,699.98% Return on Equity-104.94% Return on Assets-56.81% Debt Debt-to-Equity RatioN/A Current Ratio0.34 Quick Ratio0.34 Sales & Book Value Annual Sales$509,589.00 Price / Sales31.89 Cash FlowN/A Price / Cash FlowN/A Book Value$1.02 per share Price / Book1.01Miscellaneous Outstanding Shares15,778,000Free Float11,431,000Market Cap$16.25 million OptionableNot Optionable Beta0.33 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ABVC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThe Worst Year in American Financial History?Economist Explains: The Curse on the U.S. Dollar Yes, there is a Curse on the U.S. Dollar... and it's behin...Stansberry Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.